More NewsRead More
Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor
March 19, 2015
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial and Operational Results
March 03, 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 Cowen Health Care Conference
February 24, 2015
Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and Warrants
February 12, 2015
Biotech Industry Equities Under the Scanner - NPS Pharma, Mast Therapeutics, Threshold Pharma, Lexicon Pharma, and Regeneron Pharma
January 08, 2015
from PR Newswire
from Market News Video
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual
December 06, 2014
from Dividend Channel
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here